The American Academy of Sleep Medicine Weekly Insider keeps members informed about current AASM initiatives and the latest developments in the field of sleep medicine. Optimal Medicare NIV coverage criteria CHEST published reports from a technical expert panel involving the AASM, ATS, and AARC [...]
On July 1, 2021, the US Departments of Health and Human Services, Treasury and Labor, and the Office of Personnel Management released an interim final rule (IFR) with comment period. This IFR implements portions of the No Surprises Act legislation enacted in December 2020 [...]
The American Academy of Sleep Medicine congratulates Cathy Goldstein, MD, who was named the 2021 recipient of the Stuart Quan Award for Editorial Excellence, which recognizes the outstanding work of an associate editor of the Journal of Clinical Sleep Medicine. She was selected by [...]
Welcome to the latest edition of the AASM member magazine, Montage. In this issue, we highlight the AASM’s new clinical data registry, Sleep CDR. We also discuss the AASM-led response to a government report on the effectiveness of CPAP therapy and review the [...]
By Jennifer Gibson, AASM Communications Manager A government-sponsored draft report on the effectiveness of continuous positive airway pressure (CPAP) therapy sent shockwaves through the sleep medicine community and prompted the American Academy of Sleep Medicine (AASM) to organize a multi-society response in defense of [...]
By Jack Edinger, PhD, Chair, Behavioral and Psychological Treatments for Insomnia Guideline Task Force Chronic insomnia disorder is a widespread and debilitating condition that affects quality of life, daytime functioning, mental and physical health, and health care utilization for millions worldwide. The International Classification [...]
By Diedra Gray, AASM Director of Health Policy The American Academy of Sleep Medicine (AASM) has partnered with ArborMetrix to develop and launch the AASM Sleep Clinical Data Registry (Sleep CDR) forto the field of sleep medicine. The entire AASM quality measures portfolio is [...]
The American Academy of Sleep Medicine Weekly Insider keeps members informed about current AASM initiatives and the latest developments in the field of sleep medicine. FAQs from FDA about Philips recall The FDA has posted responses to several patient-centered questions about the Philips recall [...]
On July 28, 2021, Takeda Pharmaceutical Company announced the FDA granted Breakthrough Therapy designation to TAK-994, which may provide a future treatment option targeting the orexin deficiency underlying narcolepsy type 1. About TAK-994 TAK-994 is a Phase 2 investigational oral orexin agonist designed to [...]
The American Academy of Sleep Medicine Weekly Insider keeps members informed about current AASM initiatives and the latest developments in the field of sleep medicine. From AASM President Dr. Raman Malhotra The voluntary PAP device recall by Philips has been a challenge for our [...]